Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M.

Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25.

PMID:
30922731
2.

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.

Schmidt EV.

Semin Immunopathol. 2019 Jan;41(1):21-30. doi: 10.1007/s00281-018-0714-9. Epub 2018 Oct 29. Review.

3.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF.

J Clin Oncol. 2018 Sep 28:JCO2018789602. doi: 10.1200/JCO.2018.78.9602. [Epub ahead of print]

4.

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.

Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS.

Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28.

PMID:
30154193
5.

Region-specific alterations in astrocyte and microglia morphology following exposure to blasts in the mouse hippocampus.

DeWalt GJ, Mahajan B, Foster AR, Thompson LDE, Marttini AA, Schmidt EV, Mansuri S, D'Souza D, Patel SB, Tenenbaum M, Brandao-Viruet KI, Thompson D, Duong B, Smith DH, Blute TA, Eldred WD.

Neurosci Lett. 2018 Jan 18;664:160-166. doi: 10.1016/j.neulet.2017.11.016. Epub 2017 Nov 11.

PMID:
29133177
6.

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.

Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQM.

Clin Cancer Res. 2017 Sep 15;23(18):5349-5357. doi: 10.1158/1078-0432.CCR-17-1243. Epub 2017 Jun 20.

7.

High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.

Guertin AD, O'Neil J, Stoeck A, Reddy JA, Cristescu R, Haines BB, Hinton MC, Dorton R, Bloomfield A, Nelson M, Vetzel M, Lejnine S, Nebozhyn M, Zhang T, Loboda A, Picard KL, Schmidt EV, Dussault I, Leamon CP.

Mol Cancer Ther. 2016 Aug;15(8):1998-2008. doi: 10.1158/1535-7163.MCT-15-0950. Epub 2016 Jun 2.

8.

Immortalized myogenic cells from congenital muscular dystrophy type1A patients recapitulate aberrant caspase activation in pathogenesis: a new tool for MDC1A research.

Yoon S, Stadler G, Beermann ML, Schmidt EV, Windelborn JA, Schneiderat P, Wright WE, Miller JB.

Skelet Muscle. 2013 Dec 6;3(1):28. doi: 10.1186/2044-5040-3-28.

9.

Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.

Brudner M, Karpel M, Lear C, Chen L, Yantosca LM, Scully C, Sarraju A, Sokolovska A, Zariffard MR, Eisen DP, Mungall BA, Kotton DN, Omari A, Huang IC, Farzan M, Takahashi K, Stuart L, Stahl GL, Ezekowitz AB, Spear GT, Olinger GG, Schmidt EV, Michelow IC.

PLoS One. 2013;8(4):e60838. doi: 10.1371/journal.pone.0060838. Epub 2013 Apr 2.

10.

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics.

Chen L, Stuart L, Ohsumi TK, Burgess S, Varshney GK, Dastur A, Borowsky M, Benes C, Lacy-Hulbert A, Schmidt EV.

BMC Cancer. 2013 Feb 27;13:93. doi: 10.1186/1471-2407-13-93.

11.

The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer.

Shearin AL, Hedan B, Cadieu E, Erich SA, Schmidt EV, Faden DL, Cullen J, Abadie J, Kwon EM, Gröne A, Devauchelle P, Rimbault M, Karyadi DM, Lynch M, Galibert F, Breen M, Rutteman GR, André C, Parker HG, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1019-27. doi: 10.1158/1055-9965.EPI-12-0190-T. Epub 2012 May 23.

12.

High-dose mannose-binding lectin therapy for Ebola virus infection.

Michelow IC, Lear C, Scully C, Prugar LI, Longley CB, Yantosca LM, Ji X, Karpel M, Brudner M, Takahashi K, Spear GT, Ezekowitz RA, Schmidt EV, Olinger GG.

J Infect Dis. 2011 Jan 15;203(2):175-9. doi: 10.1093/infdis/jiq025.

13.

The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers.

Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswaran S, Chen L, Anderson KS, Ellisen LW, Sgroi D, Schmidt EV.

Cancer Res. 2011 Feb 1;71(3):937-45. doi: 10.1158/0008-5472.CAN-10-1471. Epub 2010 Dec 2.

14.

Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin.

Chang WC, Hartshorn KL, White MR, Moyo P, Michelow IC, Koziel H, Kinane BT, Schmidt EV, Fujita T, Takahashi K.

Biochem Pharmacol. 2011 Feb 1;81(3):388-95. doi: 10.1016/j.bcp.2010.10.012. Epub 2010 Oct 28.

15.

A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus.

Michelow IC, Dong M, Mungall BA, Yantosca LM, Lear C, Ji X, Karpel M, Rootes CL, Brudner M, Houen G, Eisen DP, Kinane TB, Takahashi K, Stahl GL, Olinger GG, Spear GT, Ezekowitz RA, Schmidt EV.

J Biol Chem. 2010 Aug 6;285(32):24729-39. doi: 10.1074/jbc.M110.106260. Epub 2010 Jun 1.

16.

Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression.

Yang C, Chen L, Li C, Lynch MC, Brisken C, Schmidt EV.

Mol Cell Biol. 2010 Jun;30(12):3111-25. doi: 10.1128/MCB.01398-09. Epub 2010 Apr 19.

17.

Genome-wide analysis of YY2 versus YY1 target genes.

Chen L, Shioda T, Coser KR, Lynch MC, Yang C, Schmidt EV.

Nucleic Acids Res. 2010 Jul;38(12):4011-26. doi: 10.1093/nar/gkq112. Epub 2010 Mar 9.

18.

Complex role of mannose-binding lectin in infectious diseases.

Michelow IC, Yantosca LM, Karpel M, Schmidt EV.

J Pediatr. 2009 Aug;155(2):301. doi: 10.1016/j.jpeds.2009.04.039. No abstract available.

19.

Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway.

Schmidt EV, Ravitz MJ, Chen L, Lynch M.

Cell Cycle. 2009 May 1;8(9):1344-51. Epub 2009 May 18. Review.

20.

c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.

Ravitz MJ, Chen L, Lynch M, Schmidt EV.

Cancer Res. 2007 Dec 1;67(23):11209-17.

21.
22.

Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression.

Yang C, Trent S, Ionescu-Tiba V, Lan L, Shioda T, Sgroi D, Schmidt EV.

Cancer Res. 2006 Dec 15;66(24):11649-58.

23.

Prevalence of low bone-mineral density among mentally retarded and developmentally disabled residents in intermediate care.

Schmidt EV, Byars JR, Flamuth DH, Schott JJ, Sever CM.

Consult Pharm. 2004 Jan;19(1):45-51.

PMID:
16553466
24.

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA.

Cancer Res. 2006 Feb 15;66(4):1923-8.

25.
26.

Cell-based models of sustained, interferon-sensitive hepatitis C virus genotype 1 replication.

Hiasa Y, Blackard JT, Lin W, Kamegaya Y, Horiike N, Onji M, Schmidt EV, Chung RT.

J Virol Methods. 2006 Mar;132(1-2):195-203. Epub 2005 Nov 28.

27.
28.

Hepatitis C virus expression suppresses interferon signaling by degrading STAT1.

Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV, Chung RT.

Gastroenterology. 2005 Apr;128(4):1034-41.

PMID:
15825084
29.

Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis.

Kamegaya Y, Hiasa Y, Zukerberg L, Fowler N, Blackard JT, Lin W, Choe WH, Schmidt EV, Chung RT.

Hepatology. 2005 Mar;41(3):660-7.

PMID:
15723444
30.

The role of c-myc in regulation of translation initiation.

Schmidt EV.

Oncogene. 2004 Apr 19;23(18):3217-21. Review.

PMID:
15094771
31.

The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.

Yang C, Ionescu-Tiba V, Burns K, Gadd M, Zukerberg L, Louis DN, Sgroi D, Schmidt EV.

Am J Pathol. 2004 Mar;164(3):1031-8.

32.

Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma.

Hiasa Y, Kamegaya Y, Nuriya H, Onji M, Kohara M, Schmidt EV, Chung RT.

Am J Gastroenterol. 2003 Nov;98(11):2528-34.

PMID:
14638359
33.

Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth.

Lynch M, Fitzgerald C, Johnston KA, Wang S, Schmidt EV.

J Biol Chem. 2004 Jan 30;279(5):3327-39. Epub 2003 Nov 7.

34.

Forced expression of cyclin D1 does not compensate for Id2 deficiency in the mammary gland.

Mori S, Inoshima K, Shima Y, Schmidt EV, Yokota Y.

FEBS Lett. 2003 Sep 11;551(1-3):123-7.

36.
37.

Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors.

Miyoshi K, Rosner A, Nozawa M, Byrd C, Morgan F, Landesman-Bollag E, Xu X, Seldin DC, Schmidt EV, Taketo MM, Robinson GW, Cardiff RD, Hennighausen L.

Oncogene. 2002 Aug 15;21(36):5548-56.

38.

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT.

J Virol. 2002 Sep;76(17):8505-17.

39.

Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.

Nahta R, Iglehart JD, Kempkes B, Schmidt EV.

Cancer Res. 2002 Apr 15;62(8):2267-71.

40.

Regulation of cyclin D1 and p16(INK4A) is critical for growth arrest during mammary involution.

Gadd M, Pisc C, Branda J, Ionescu-Tiba V, Nikolic Z, Yang C, Wang T, Shackleford GM, Cardiff RD, Schmidt EV.

Cancer Res. 2001 Dec 15;61(24):8811-9.

41.

IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development.

Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M.

Cell. 2001 Dec 14;107(6):763-75.

42.

In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53.

Hosokawa Y, Papanikolaou A, Cardiff RD, Yoshimoto K, Bernstein M, Wang TC, Schmidt EV, Arnold A.

Transgenic Res. 2001 Oct;10(5):471-8.

PMID:
11708657
43.

Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system.

Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, Wang TC, Schmidt EV.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9847-52. Epub 2001 Aug 7.

44.

Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.

Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A.

J Clin Invest. 2001 May;107(9):1093-102.

45.

Meningococcal disease among children who live in a large metropolitan area, 1981-1996.

Wang VJ, Kuppermann N, Malley R, Barnett ED, Meissner HC, Schmidt EV, Fleisher GR.

Clin Infect Dis. 2001 Apr 1;32(7):1004-9. Epub 2001 Mar 15.

PMID:
11264027
46.

Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination.

Ambati BK, Ambati J, Azar N, Stratton L, Schmidt EV.

Ophthalmology. 2000 Aug;107(8):1450-3.

PMID:
10919886
47.
48.

CDC64 encodes cytoplasmic alanyl-tRNA synthetase, Ala1p, of Saccharomyces cerevisiae.

Wrobel C, Schmidt EV, Polymenis M.

J Bacteriol. 1999 Dec;181(24):7618-20.

49.

The role of c-myc in cellular growth control.

Schmidt EV.

Oncogene. 1999 May 13;18(19):2988-96. Review.

50.

Coordination of cell growth with cell division.

Polymenis M, Schmidt EV.

Curr Opin Genet Dev. 1999 Feb;9(1):76-80. Review.

PMID:
10072360

Supplemental Content

Loading ...
Support Center